Compare FRT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRT | JAZZ |
|---|---|---|
| Founded | 1962 | 2003 |
| Country | United States | Ireland |
| Employees | 320 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 10.4B |
| IPO Year | N/A | 2007 |
| Metric | FRT | JAZZ |
|---|---|---|
| Price | $102.78 | $182.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $111.87 | ★ $216.92 |
| AVG Volume (30 Days) | 622.0K | ★ 728.5K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $5.86 | $6.17 |
| Revenue Next Year | $4.50 | $7.66 |
| P/E Ratio | $22.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.65 | $95.49 |
| 52 Week High | $110.89 | $198.00 |
| Indicator | FRT | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 54.62 |
| Support Level | $98.70 | $176.67 |
| Resistance Level | $108.54 | $198.00 |
| Average True Range (ATR) | 1.69 | 4.50 |
| MACD | -0.52 | -0.10 |
| Stochastic Oscillator | 8.25 | 50.55 |
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 102 properties, which includes 27.4 million square feet of retail space and 3,000 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.